<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Phil</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Toso, Anna</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">High-Dose Rosuvastatin Reduces Contrast-Induced Nephropathy</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013-04-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">14-15</style></pages><abstract><style  face="normal" font="default" size="100%">Among statin-naïve patients with non-ST-segment elevation acute coronary syndrome managed with an early invasive strategy, pretreatment with high-dose rosuvastatin was associated with a significant reduction in the incidence of contrast-induced acute kidney injury. In addition, pretreatment with rosuvastatin was also associated with a reduction in adverse clinical events at 30 days compared with placebo. This article presents the results of the Protective Effect of Rosuvastatin and Antiplatelet Therapy on Contrast-Induced Acute Kidney Injury and Myocardial Damage in Patients With Acute Coronary Syndrome study [PRATO-ACS; NCT01185938].</style></abstract><number><style face="normal" font="default" size="100%">2</style></number><volume><style face="normal" font="default" size="100%">13</style></volume></record></records></xml>